A 510(k) is a clearance based on showing a device is substantially equivalent to one already on the market; a PMA is a full approval requiring clinical evidence that a high-risk device is safe and effective on its own. The 510(k) is faster and cheaper and covers most devices; the PMA is rigorous, expensive, and reserved for the riskiest. Which one your device needs is decided mostly by its risk class. Here is how the system works.
It starts with risk class
The FDA sorts medical devices into three classes by risk, and the class largely dictates the regulatory pathway.
- Class I devices are low-risk, think bandages or basic surgical instruments, and most are exempt from premarket review entirely.
- Class II devices are moderate-risk, think infusion pumps or many diagnostic devices, and most reach the market through the 510(k) pathway.
- Class III devices are high-risk, typically those that sustain life or could cause serious harm if they fail, think implantable pacemakers or heart valves, and these generally require the more demanding PMA.
So before anything else, a device’s risk class points to which door it will use. Get the classification right and the pathway usually follows.
The 510(k): clearance by comparison
The 510(k) pathway, named after a section of the law, is how the majority of moderate-risk devices reach the market. Its central idea is substantial equivalence: rather than proving the device is safe and effective from scratch, the manufacturer demonstrates that it is substantially equivalent to a device already legally on the market, called a predicate. If your new device has the same intended use and similar technological characteristics as an existing one, and any differences do not raise new safety or effectiveness questions, the FDA can clear it based on that comparison. This is why devices are said to be cleared, not approved, through a 510(k). Because it leans on an existing predicate, the 510(k) is faster and far less expensive than a full approval, and it often does not require new clinical trials, though it can. It is the workhorse of the medtech industry.
The PMA: approval on your own merits
For the highest-risk Class III devices, substantial equivalence is not enough; the stakes are too high to rely on comparison to a predicate. These devices go through Premarket Approval, the FDA’s most stringent device pathway. A PMA requires the manufacturer to provide robust scientific evidence, typically including clinical trial data, that the device is safe and effective for its intended use on its own merits. The review is deep and can involve advisory panels, much like a new drug. Because of that rigor, a PMA takes far longer and costs far more than a 510(k), and it is why a device that clears PMA is described as approved rather than merely cleared. The tradeoff for that burden is a much stronger market position, since competitors face the same steep barrier.
The De Novo route: for the genuinely new
What about a device that is low or moderate risk but so novel that no predicate exists? It would be unfair to force a truly innovative but low-risk device through the full PMA process just because nothing like it came before. For exactly this situation there is the De Novo pathway, which lets a novel low-to-moderate-risk device be classified and authorized without an existing predicate, and in doing so it can become the predicate that future 510(k)s reference. The De Novo route has become an important pathway for genuinely new technologies, including many software and digital-health devices, that do not fit the older mold.
The pathways at a glance
| Pathway | For | Standard | Result | Effort |
|---|---|---|---|---|
| 510(k) | Most Class II devices | Substantial equivalence to a predicate | Cleared | Moderate |
| PMA | Most Class III (high-risk) devices | Independent safety and effectiveness | Approved | High |
| De Novo | Novel low-to-moderate-risk devices with no predicate | Risk-based classification | Authorized (granted) | Moderate to high |
Why the distinction matters commercially
The pathway you take shapes your entire business plan: your timeline, your budget, your evidence requirements, and your competitive position. A 510(k) device can often reach the market in a fraction of the time and cost of a PMA device, but it also faces easier competition, since rivals can use the same or similar predicates. A PMA device demands a heavy, expensive, clinical-evidence-driven effort, but that same barrier keeps competitors out. Choosing, and correctly justifying, the right pathway is one of the most consequential regulatory decisions a medtech company makes, and getting the device classification wrong can cost years. The words matter too: saying a device is FDA-approved when it was actually 510(k)-cleared is a common and meaningful error.
The bottom line
Most devices reach the market through the 510(k) pathway by showing they are substantially equivalent to something already sold, and they are cleared. The riskiest devices go through PMA, proving their own safety and effectiveness with clinical data, and they are approved. Genuinely novel low-risk devices use the De Novo route. Behind all three sits the same organizing logic: the higher the risk, the higher the bar. Learn a device’s risk class, and its regulatory road usually reveals itself.
The evidence and timeline reality
The gap between the two main pathways is not just procedural; it shows up starkly in time, money, and evidence, and it shapes how medtech companies build their businesses. A 510(k) submission, resting on comparison to an existing predicate device, can often be prepared and cleared in a matter of months and frequently without a new clinical trial, which is why it is the default route for the flood of moderate-risk devices that reach the market each year. A PMA is a different order of magnitude: it typically requires substantial clinical evidence gathered from purpose-run studies, and the preparation and review can stretch over years and cost many times what a 510(k) demands. That difference drives real strategic choices, including where a company sets the intended use and technological profile of its device to fit, honestly, the pathway it can afford. The reliance on predicates has drawn debate, since a long chain of devices cleared by equivalence to earlier devices can drift over time, and regulators continue to refine how the system handles that. Both pathways also come with obligations that do not end at market entry: manufacturers face ongoing requirements around quality systems, adverse-event reporting, and sometimes post-market studies, so clearance or approval is the beginning of a compliance relationship, not the end of one. A growing wrinkle is software: as more medical devices are software, including AI-enabled tools, regulators have adapted these pathways and added routes like De Novo to handle technologies the original framework never anticipated. For any medtech founder, the practical message is that the regulatory pathway is not a box to tick at the end but a decision that should shape the product strategy, the budget, and the timeline from the very beginning.
Get the classification right first
If there is one thing to take away, it is that everything downstream flows from the device’s risk classification, so getting that right at the very start is the highest-leverage regulatory decision a medtech company makes. Misjudge the class, and you can waste years preparing for the wrong pathway or, worse, discover late that your device requires a far heavier evidence burden than you planned and budgeted for. Because classification hinges on the device’s intended use and technological characteristics, the way you define and describe your product has direct regulatory and commercial consequences, and it is worth getting expert input early rather than assuming. The pathway then shapes your clinical evidence plan, your timeline, your budget, and your competitive position, which is why experienced medtech teams treat the regulatory strategy as a founding decision, made alongside the product design, not a compliance step bolted on at the end. Start from the risk class, define the intended use with care, and the rest of the regulatory road becomes far more predictable.
For daily coverage of the clearances, approvals, and launches shaping medtech, the BioMed Nexus brief tracks them as they happen, and the medical device companies directory maps the companies building across the field, from established players to the startups navigating these pathways for the first time.
Frequently asked questions
What is the difference between a 510(k) and a PMA?
A 510(k) clears a device by showing it is substantially equivalent to a device already on the market (a predicate), and is used for most moderate-risk Class II devices. A PMA (Premarket Approval) requires independent clinical evidence that a high-risk Class III device is safe and effective on its own, and is far more demanding.
Is a 510(k) device FDA-approved?
No. Devices that go through the 510(k) pathway are FDA-cleared, not approved, because clearance is based on substantial equivalence to an existing device rather than independent proof of safety and effectiveness. Only devices that complete the more rigorous PMA pathway are described as FDA-approved.
What is the De Novo pathway?
The De Novo pathway lets a novel low-to-moderate-risk device be classified and authorized when no suitable predicate device exists, so it does not have to go through the full PMA process. A De Novo authorization can itself become the predicate that future 510(k) submissions reference, and it is common for innovative software and digital-health devices.
